503614-91-3

• 常用中文名：1-(4-甲氧基苯基)-7-氧代-6-[4-(2-氧代哌啶-1-基)苯基]-4,5,6,7-四氢-1H-吡唑并[3,4-C]吡啶-3-羧酸乙酯
• 常用英文名：1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
• CAS号：503614-91-3
• 分子式：C₂₇H₂₈N₄O₅
• 分子量：488.535
• 发布时间：2018-12-06 19:15:52
• 更新时间：2026-07-16 19:28:34

名称

• 中文名: 4,5,6,7-四氢-1-(4-甲氧基苯基)-7-氧代-6-[4-(2-氧代-1-哌啶基)苯基]-1H-吡唑并[3,4-c]吡啶-3-羧酸乙酯
• 英文名: ethyl 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxylate
• 中文别名: 阿哌沙班乙酯杂质; 阿哌沙班相关杂质; 1-(4-甲氧基苯基)-7-酮-6-(4-(2-哌啶酮-1-)苯基)-4,5,6,7-四氢-1H-吡唑[3,4-C]吡啶-3-甲酸乙酯; APIXABAN ESTER 杂质; 1H-吡唑并[3,4-C]吡啶-3-甲酸, 4,5,6,7-四氢-1-(4-甲氧基苯基)-7-氧代-6-[4-(2-氧代-1-哌啶基)苯基]-, 乙酯; 阿哌沙班中间体N-1; 阿哌沙班杂质 9; 1-(4-甲氧基苯基)-7-氧代-6-[4-(2-氧代哌啶-1-基)苯基]-4,5,6,7-四氢-1H-吡唑并[3,4-C]吡啶-3-羧酸乙酯1-(4-Methoxyphenyl)-x-[4-(xopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo|3,4-c]pyridine-3-cboxylic acid ethyl ester; 阿哌沙班05; 阿哌沙班乙酯 (阿哌沙班N-1杂质); 4,5,6,7-四氢-1-(4-甲氧基苯基)-7-氧代-6-[4-(2-氧代-1-哌啶基)苯基]-1H-吡唑并[3,4-C]吡啶-3-羧酸乙酯; 阿哌沙班杂质C对照品; A阿哌沙班杂质C; 阿哌沙班杂质C(BMS-589154-01); 1-(4-甲氧基苯基)-7-氧代-6-[4-(2-氧代哌啶-1-基)苯基]-4,5,6,7-四氢-1H-吡唑并[3,4-C]吡啶-3-羧酸乙酯(阿哌沙班中间体); 1-(4-甲氧基苯基)-7-氧代-6-[4-(2-氧代哌啶-1-基)苯基]-4,5,6,7-四氢-1H-吡唑并[3,4-C]吡啶-3-甲酸乙酯; 阿派沙班杂质9/阿呱沙班杂质D; 1-(4-甲氧基苯基)-7-氧代-6-[4-(2-氧代哌啶-1-基)苯基]-4,5,6,7-四氢-1H-吡唑并[3,4-C]吡啶-3-羧酸乙酯 1-(4-METHOXYPHENYL)-7-OXO-6-[4-(2-OXOPIPERIDIN-1-YL)PHENYL]-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDINE-3-CBOXYLIC ACID ETHYL ESTER; 阿哌沙班N-1; 阿哌沙班中间体N-1 (503-3); 阿哌沙班乙酯; 阿哌沙班杂质BZ; 阿哌沙班中间体C; 阿哌沙班杂质9(BMS-589149-01); 1-(4-甲氧基苯基)-7-氧代-6-(4-(2-氧代哌啶-1-基)苯基-4,5,6,7-四氢-1H-吡唑[3,4-C]吡啶-3-甲酸乙酯; 1-(4-甲氧基苯基)-7-氧代-6-[4-(2-氧代哌啶-1-基)苯基j-45,6,7-四氢-1H-吡唑并[3,4-c]吡啶-3-羧酸乙酯; 进口资料代码-BMS-589149-01; 阿哌沙班杂质; 阿派沙班杂质V
• 英文别名: BMS-589149-01; Apixaban-3; 7-oxo-6-(4-(2-oxopiperidin-1-yl); 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-cboxylic acid ethyl 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-cboxylic acid e; Ethyl 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[; ethyl 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate; 1H-Pyrazolo[3,4-c]pyridine-3-carboxylic acid, 4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-, ethyl ester; Apixaban ethyl ester impuity Ethyl 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1- yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3- cboxylate; ethyl 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxo-1-piperidinyl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-cboxylate; Ethyl 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate; Apixaban Ethyl Ester; 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-cboxylate; 4,5,6,7-Tetrahydro-1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-1h-pyrazolo[3,4-c]pyridine-3-cboxylic acid ethyl ester; 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyr; 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo; 1H-Pyrazolo[3,4-c]pyridine-3-cboxylicacid,4,5,6,7-tetrahydro-1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-,ethylester; Ethyl 1-(4-methoxyphenyl); Apixaba inretMediate C; ethyl 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H; Ethyl 1-(4-Methoxyphenyl)-7-Oxo-6-(4-(2-Oxopiperidin-1-Yl; Ethyl 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazo; Impurity of apixaban381; 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-1H-Pyrazolo[3,4-c]pyridine-3-cboxylic acid ethyl ester; Apixaban Ester Impurity; Apixaban Impurity BZ; ethyl 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-cboxylate; TECO-008; Ethyl 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1yl)phenyl)-4,5,6,7-tetrahydro-1H- pyrozolo[3,4-c] pyridine-3-cboxylate; Apixaban Ethyl Ester Imp; ethyl 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate; Apixaban INT 02; 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-cboxylic acid ethyl ester; T56 BNN HNV&TJ BR DO1& DVO2 HR D- AT6NVTJ; Apixaban Impurity C ethyl; ApixabanIm purit; 1-(4-methoxy-phenyl)-7-oxo-6-[4-(2-oxo-piperidin-1-yl)-phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester; 4-c]pyridine-3-cboxylic acid ethyl ester; Apixaban Impurity 9 (BMS-589149-01); 4,5,6,7-Tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid; BMS-589154)）; Apixaban Ethyl ester Impurity; 1-(4-Methoxyphenyl)-7-oxo -6-[4-(2-oxopiperidin-1-yl) phenyl]-4,5,6,7-tetrahydro- 1H-pyrazolo[3,4-c]pyridine -3-cboxylic acid ethyl este; 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4; Apixaban Intermediate 4,5,6,7; 1-(4-methoxyphenyl)-6-[4-(2-oxo-piperidinyl)phenyl]-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester; Apixaban N-1; FaX-IN-1; APIXABAN V; BMS-589154); Apixaban V

物化性质

• 密度: 1.3±0.1 g/cm3
• 沸点: 758.7±60.0 °C at 760 mmHg
• 分子式: C₂₇H₂₈N₄O₅
• 分子量: 488.535
• 闪点: 412.6±32.9 °C
• 精确质量: 488.205963
• PSA: 93.97000
• LogP: 2.47
• 蒸汽压: 0.0±2.6 mmHg at 25°C
• 折射率: 1.658
• 储存条件: 室温，干燥密封

合成路线

上下游产品

上游产品  9
675-20-7 473927-64-9 545445-44-1 473927-63-8
881386-12-5 104-94-9 27143-07-3 1415831-80-9
1267610-26-3
下游产品  0